» Articles » PMID: 32170383

Optimization and Validation of a Blocking ELISA for Quantitation of Anti-rabies Immunoglobulins in Multispecies Sera

Overview
Date 2020 Mar 15
PMID 32170383
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We developed a fast, rabies virus-free, in vitro method, based on a blocking ELISA (bELISA), to detect and accurately quantify anti-rabies glycoprotein antibodies in serum of several animal species. In this method, purified rabies virus-like particles (VLPs) are used as antigen to coat the plates, while the presence of specific rabies immunoglobulins is revealed through blocking the recognition of these VLPs by a biotinylated monoclonal antibody. A quality by design approach was carried out in order to optimize the method performance, improving the sensitivity and, thereby, reducing the limit of detection of this assay. After the method validation, we confirmed that the bELISA method is able to detect a concentration of 0.06 IU/mL rabies immunoglobulins, titer lower than the 0.5 IU/mL cutoff value established as indication for correct vaccination. Further, we assessed the correlation between bELISA, the MNT, and the Platelia methods, confirming the accuracy of this new assay. On the other hand, precision was evaluated, obtaining acceptable repeatability and intermediate precision values, showing that this bELISA could be proposed as a potential alternative method, replacing the gold standard techniques in vaccination schemes and becoming a routine control technique within regional rabies surveillance programs.

Citing Articles

Evaluation of the immune status of dogs vaccinated against rabies by an enzyme-linked immunosorbent assay using crude preparations of insect cells infected with a recombinant baculovirus encoding the rabies virus glycoprotein gene.

Santosh A, Kumar D, Kaur C, Gupta P, Jasmeen P, Dilip L PLoS One. 2024; 19(12):e0314516.

PMID: 39625902 PMC: 11614288. DOI: 10.1371/journal.pone.0314516.


Rational design of novel fusion rabies glycoproteins displaying a major antigenic site of foot-and-mouth disease virus for vaccine applications.

Garay E, Fontana D, Leschiutta L, Kratje R, Prieto C Appl Microbiol Biotechnol. 2021; 106(2):579-592.

PMID: 34971413 PMC: 8718594. DOI: 10.1007/s00253-021-11747-4.


Detection and quantification of anti-rabies glycoprotein antibodies: current state and perspectives.

Rodriguez M, Fontana D, Garay E, Prieto C Appl Microbiol Biotechnol. 2021; 105(18):6547-6557.

PMID: 34448897 PMC: 8390338. DOI: 10.1007/s00253-021-11515-4.


Chimeric VLPs Based on HIV-1 Gag and a Fusion Rabies Glycoprotein Induce Specific Antibodies against Rabies and Foot-and-Mouth Disease Virus.

Fontana D, Garay E, Cervera L, Kratje R, Prieto C, Godia F Vaccines (Basel). 2021; 9(3).

PMID: 33809060 PMC: 7999769. DOI: 10.3390/vaccines9030251.


Increase in lipid productivity and photosynthetic activities during distillery wastewater decolorization by Chlorella vulgaris cultures.

Soleymani Robati S, Nosrati M, Ghanati F, Hajnowrouzi A, Grizeau D, Dupre C Appl Microbiol Biotechnol. 2021; 105(8):3339-3351.

PMID: 33783589 DOI: 10.1007/s00253-021-11233-x.

References
1.
Cliquet F, McElhinney L, Servat A, Boucher J, Lowings J, Goddard T . Development of a qualitative indirect ELISA for the measurement of rabies virus-specific antibodies from vaccinated dogs and cats. J Virol Methods. 2004; 117(1):1-8. DOI: 10.1016/j.jviromet.2003.12.001. View

2.
Ertl H . Novel vaccines to human rabies. PLoS Negl Trop Dis. 2009; 3(9):e515. PMC: 2742899. DOI: 10.1371/journal.pntd.0000515. View

3.
Feyssaguet M, Dacheux L, Audry L, Compoint A, Morize J, Blanchard I . Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and.... Vaccine. 2007; 25(12):2244-51. DOI: 10.1016/j.vaccine.2006.12.012. View

4.
Fontana D, Marsili F, Garay E, Battagliotti J, Etcheverrigaray M, Kratje R . A simplified roller bottle platform for the production of a new generation VLPs rabies vaccine for veterinary applications. Comp Immunol Microbiol Infect Dis. 2019; 65:70-75. DOI: 10.1016/j.cimid.2019.04.009. View

5.
Korimbocus J, Dehay N, Tordo N, Cano F, Morgeaux S . Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use. Vaccine. 2016; 34(28):3310-6. DOI: 10.1016/j.vaccine.2016.04.086. View